ASRT Lead Plaintiff Deadline Approaching

Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed against Assertio Holdings, Inc. (ASRT)

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of Illinois against Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT). The action charges Assertio with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects. As a result of Assertio’ s materially misleading statements and omissions to the public, Assertio’s investors have suffered significant losses.

CLICK HERE TO SUBMIT YOUR ASSERTIO LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/assertio-holdings-inc?utm_source=PR&amp ...

LEAD PLAINTIFF DEADLINE: MARCH 5, 2024

CLASS PERIOD: MARCH 9, 2023 THROUGH NOVEMBER 8, 2023

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
Jonathan Naji, Esq. at [phone] or via email at [e-mail]

Kessler Topaz is one of the world’s foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field as well as the firm itself which is continuously awarded for the successful results we’ve achieved. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.

In addition to representing investors in cases where the fraud has been revealed, Kessler Topaz also represents whistleblowers - persons who expose wrongdoing to those in positions of authority or to the public- in cases brought under federal and state qui tam statutes, and through financial fraud whistleblower programs, such as those run by the SEC, CFTC and IRS. If you have information about fraud against government programs (such as Medicare), or violations of federal securities, commodities, tax or anti-foreign bribery laws, contact Kessler Topaz at [phone] or at [e-mail] or go to https://www.ktmc-whistleblower.com.

ASSERTIO’S ALLEGED MISCONDUCT
In July 2023, Assertio acquired Spectrum Pharmaceuticals, Inc. ("Spectrum"), a biopharmaceutical company focused on novel and targeted oncology, along with Spectrum's injection asset Rolvedon. In a press release announcing the closing of the acquisition, Assertio's CEO stated, "[w]e look forward to building on the successful early results in the [Rolvedon] Injection launch for the remainder of 2023, driving the business toward [its] goal of accretive contribution to our Adjusted EPS and operating cash flow in 2024."